See more information about SH-NOMEN and learn more about the use of valves
Leading enterprises will spark the industry’s next explosive growth.
Amid the wave of high-quality industry development,
every breakthrough achieved by a leading enterprise injects new momentum into industrial upgrading.
SH-NOMEN remains steadfast in advancing the innovation and practical application of next-generation valve technologies.
Today, we officially launch the “100 Benchmark Enterprises Empowerment Program.”
In the coming year,
we will deeply empower 100 industry-representative benchmark enterprises,
delivering tailored solutions and best-value offerings
to propel their production efficiency and quality control to unprecedented heights.
Why do we need “benchmark enterprises”?
In recent years, every technological leap and every production-line upgrade in the pharmaceutical industry has been driven by deep co-creation between equipment suppliers and leading enterprises.
Through this program,
we aim to forge strategic partnerships with leading enterprises across all sectors and regions,
jointly uncovering the optimal solutions for pharmaceutical valves in extreme environments,
high-precision control,
and compliant production—propelling industry standards to the next level.
Who qualifies as our “Benchmark Enterprise”?
Our criteria span the entire industry,
every scenario and every region
no matter which sector you belong to,
you’re welcome to apply as long as you meet the corresponding requirements!
宝马（德国）电池高压工厂
1. By Industry Sector
From biologics to food, from semiconductors to petrochemicals, every high-end link in the value chain demands reliable valve solutions.
Benchmark Criteria: Companies with 10+ years of industry experience, or annual revenue exceeding RMB 300 million in their niche, or top-three domestic market share, and which have achieved outstanding results in process innovation and quality control.
半导体生产线
2. Categorized by Company Size
• Emerging Biotechs: Smaller-scale innovators with breakthroughs in cutting-edge modalities such as mRNA or gene therapy.
Benchmark Criteria: Meeting any one of the above conditions, or annual valve procurement exceeding RMB 2 million, or presenting a documented capacity-expansion plan.
3. Segmentation by regional market
Central and Western China: Generic drug upgrading and traditional Chinese medicine modernization enterprises in Chengdu, Wuhan and Xi'an;
Northeast China: Benchmark enterprises with over 10 years of experience in the industry in Heilongjiang, Jilin, Liaoning and other provinces.
What will you get if you meet the benchmark criteria?
Being a "benchmark enterprise" means that your company is a true industry leader.
✅Complimentary process diagnosis: a team of senior engineers will be on-site to accurately identify production bottlenecks.
✅Tailor-made solutions: for every specific operating condition and scenario, we deliver cost-optimized, special-material valve designs engineered for extreme environments.
✅Annual Co-Branding Exposure: We regularly showcase our joint achievements at industry summits and in authoritative media. Based on content you provide, we arrange targeted publicity in both domestic and international outlets to elevate your brand influence.
✅Long-term strategic partnership: enjoy exclusive pricing and guaranteed supply-chain priority, cutting your procurement costs.
Welcome to Contact Us
every link in production safety deserves our unwavering care.
SH-NOMEN looks forward to joining hands with 100 benchmark enterprises,
using technology as the pen and partnership as the paper to co-write the next chapter of China’s pharmaceutical equipment!
